Key result
Sirolimus-eluting resorbable magnesium scaffolds yield ~6% VOCE rate at 3.5 years in selected patients.
Why the study?
The resorbable magnesium scaffold (RMS) had shown conflicting results in previous studies, suggesting that patient selection and implantation technique may impact clinical outcomes. This study investigated the safety and long-term effectiveness of RMS in a narrowly selected population with standardized implantation.
What are the 1-year and long-term vessel-oriented composite outcomes of sirolimus-eluting resorbable magnesium scaffold implantation using strict patient selection and standardized implantation techniques in patients undergoing PCI?
Cohort (n=543)
Yes
What are the 1-year and long-term vessel-oriented composite outcomes of sirolimus-eluting resorbable magnesium scaffold implantation using strict patient selection and standardized implantation techniques in patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
Strict patient selection and standardized implantation techniques with sirolimus-eluting resorbable magnesium scaffolds yield low long-term adverse event and scaffold thrombosis rates comparable to second-generation DES in MI patients.
BACKGROUND: The resorbable magnesium scaffold (RMS) is a second-generation bioresorbable scaffold (BRS) that has shown conflicting results in previous studies. These findings suggest that patient selection and implantation technique may have an impact on clinical outcomes. This study aimed to investigate the safety and long-term effectiveness of RMS in a narrowly selected population. METHODS: SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolled patients undergoing BRS coronary implantation in 18 Italian centers. The present analysis considered the first 543 enrolled patients treated with RMS, with a minimum follow-up of 1 year. The study protocol included strict criteria for patient selection and standardization of RMS implantation. The primary outcome was the occurrence of the vessel-oriented composite endpoints (VOCE), including cardiac death, target vessel myocardial infarction, and ischemia-driven target vessel revascularization. RESULTS: Overall, 635 vessels were treated. The 1-year cumulative occurrence of VOCE was 22 (3.5%, 95% CI 2.2%-5.2%), which was significantly lower than the prespecified estimation (from 5.5% to 8.5%). At the median follow-up of 3.5 [2.6-4.3] years, there were 3 (0.5%) cardiac deaths, 12 (1.9%) target vessel myocardial infarctions, and 33 (5.2%) ischemia-driven target vessel revascularizations. A total of 37 (5.8%, 95%CI 4.1%-7.9%) VOCEs were detected. Scaffold thrombosis occurred in 4 (0.6%, 95%CI 0.1%-1.6%) cases. Patient-level analysis confirmed the findings of the vessel-level analysis. CONCLUSIONS: These results confirm the safety and performance of RMS technology. If confirmed in randomized controlled trials, they may rekindle interest in the use of scaffolds in daily practice.
No takes yet. Share an insight, caveat, or question.
Pompei et al. (2023) conducted a cohort in Coronary artery disease undergoing percutaneous coronary intervention (74% myocardial infarction, 26% chronic coronary syndrome) (n=543). Sirolimus-eluting resorbable magnesium scaffold (RMS, Magmaris) implantation with standardized technique vs. Prespecified performance goal (5.5% to 8.5% 1-year VOCE); secondary propensity-matched cohort of 402 MI patients treated with second-generation DES from the ARYOSTO registry was evaluated on Vessel-oriented composite endpoints (VOCE: cardiac death, target vessel myocardial infarction, and ischemia-driven target vessel revascularization) at 1 year and longest follow-up (median 3.5 years) (95% CI 4.1%-7.9%). Sirolimus-eluting resorbable magnesium scaffold implantation resulted in a 1-year VOCE rate of 3.5% and a 3.5-year rate of 5.8% in selected patients.
Synapse has enriched 10 related papers. Consider them for comparative context: